We are live on ! Find out more
NIVF

NewGenIvf
NIVF

3 hedge funds and large institutions have $3.85K invested in NewGenIvf in 2026 Q1 according to their latest regulatory filings, with 2 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

8,865% more capital invested

Capital invested by funds: $43 → $3.85K (+$3.81K)

200% more funds holding

Funds holding: 1 → 3 (+2)

0.01% more ownership

Funds ownership: 0% → 0.01% (+0.01%)

Holders
3
Holders Change
+2
Holders Change %
+200%
% of All Funds
0.04%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
TRCT
Tower Research Capital (TRC)
New York
+$6.08K
2
UBS Group
UBS Group
Switzerland
+$800

Top Sellers

No sellers this quarter

NIVF Hedge Fund Activity: Q1 2026 in Review

3 of the 8,208 institutional investors tracked by Wall St. Rank reported a position in NewGenIvf (NIVF) for Q1 2026, worth a combined $3.85K — up 8,865% from $43 a quarter earlier.

Buyers outnumbered sellers: 2 funds opened new NIVF positions and 0 closed out — a net gain of 2 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was Tower Research Capital (TRC), opening a new position worth an estimated $6.08K.

  • 3 institutional investors held NewGenIvf (NIVF) as of Q1 2026, up from 1 in Q4 2025.
  • Funds reported $3.85K of NewGenIvf stock for Q1 2026, up 8,865% quarter-over-quarter.
  • 2 funds opened new NewGenIvf positions in Q1 2026 and 0 closed out, a net change of +2 holders.
  • The largest NewGenIvf buyer in Q1 2026 was Tower Research Capital (TRC), an estimated $6.08K added.

Based on aggregated 13F filings for Q1 2026.